PHAR vs. ZYME, LYEL, ORIC, OLMA, GHRS, SLN, STOK, CVAC, CALT, and PAHC
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Zymeworks (ZYME), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA), GH Research (GHRS), Silence Therapeutics (SLN), Stoke Therapeutics (STOK), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical preparations" industry.
Pharming Group (NASDAQ:PHAR) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 1.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Pharming Group has a net margin of -4.01% compared to Zymeworks' net margin of -249.63%. Pharming Group's return on equity of -4.61% beat Zymeworks' return on equity.
Pharming Group has higher revenue and earnings than Zymeworks. Pharming Group is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Pharming Group has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
Pharming Group presently has a consensus target price of $37.00, suggesting a potential upside of 296.15%. Zymeworks has a consensus target price of $12.67, suggesting a potential upside of 37.98%. Given Pharming Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pharming Group is more favorable than Zymeworks.
In the previous week, Pharming Group had 13 more articles in the media than Zymeworks. MarketBeat recorded 16 mentions for Pharming Group and 3 mentions for Zymeworks. Pharming Group's average media sentiment score of 0.64 beat Zymeworks' score of 0.17 indicating that Pharming Group is being referred to more favorably in the media.
Zymeworks received 275 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 68.59% of users gave Zymeworks an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
Summary
Pharming Group beats Zymeworks on 11 of the 18 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
